Work

Gut hormone polyagonists for the treatment of type 2 diabetes

Year: 2018
Type: review
Abstract: • Unimolecular agonists targeting the receptors for GLP-1, GIP and Glucagon offer therapeutic value for the treatment of the metabolic syndrome. • Peptide-mediated nuclear hormone delivery is an innovative approach for novel pharmacotherapies. Chemical derivatives of the gut-derived peptide hormone glucagon-like peptide 1 (GLP-1) are among the best-in-class pharmacotherapies to treat obesity and type 2 diabetes. However, GLP-1 analogs have modest weight lowering capacity, in the range of 5–10%, and the therapeutic window is hampered by dose-dependent side effects. Over the last few years, a new concept has emerged: combining the beneficial effects of several key metabolic hormones into a single molecular entity. Several unimolecular GLP-1-based polyagonists have shown superior metabolic action compared to GLP-1 monotherapies. In this review article, we highlight the history of polyagonists targeting the receptors for GLP-1, GIP and glucagon, and discuss recent progress in expanding of this concept to now allow targeted delivery of nuclear hormones via GLP-1 and other gut hormones, as a novel approach towards more personalized pharmacotherapies.
Source: Peptides
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,710
OpenAlex ID: W2788969344
FWCI: 2.413
Cites: 213
Cited by: 110
Related to: 9